Long-Term Outcomes After Transcatheter Tricuspid Valve-in-Valve Replacement

医学 外科 假肢 人口 阀门更换 三尖瓣 假体设计 三尖瓣狭窄 并发症 心脏病学
作者
Émile Voisine,Juan Hernando Del Portillo,Laurent Desjardins,Christine Houde,Jean Perron,Frédéric Jacques,Philippe Chétaille,François Philippon,Émilie Laflamme,Élisabeth Bédard,Josep Rodés‐Cabau
出处
期刊:Journal of Invasive Cardiology [HMP Global Learning Network]
卷期号:37 (12) 被引量:2
标识
DOI:10.25270/jic/25.00266
摘要

OBJECTIVES: Transcatheter tricuspid valve-in-valve (ViV) replacement has emerged as a less invasive alternative to redo surgery in patients with failing bioprosthetic tricuspid valves. While short- and mid-term outcomes have been reported, data on long-term follow-up remain limited. METHODS: The authors conducted a single-center observational study including 12 consecutive patients who underwent transcatheter tricuspid ViV replacement. Clinical, echocardiographic, and procedural data were prospectively collected. Patients were followed at 1 and 12 months, and yearly thereafter; follow-up included annual clinical visits and echocardiography. RESULTS: The mean age of the patients was 45 years (range, 23-69 years); 92% were women, and the indication for ViV was prosthetic valve regurgitation in most (58%) cases. A balloon-expandable SAPIEN valve (Edwards Lifesciences) was implanted in all cases, with 100% procedural success. After a mean follow-up of 6 years (range, 1-11 years), 3 (25%) patients died, and 1 was readmitted because of heart failure. Functional status improved significantly, with all surviving patients in New York Heart Association class I or II at last follow-up. Transvalvular gradients remained stable over time in 83% of the patients. Two (17%) patients developed bioprosthetic valve dysfunction during follow-up: one due to significant tricuspid stenosis and the other due to severe tricuspid regurgitation. CONCLUSIONS: Tricuspid ViV replacement offers durable symptomatic improvement and stable prosthesis function during long-term follow-up in most cases. This study is the first to report outcomes greater than or equal to 5 years in this population and supports the continued use of ViV as a viable option for these patients. Larger studies are warranted to validate these findings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
zyx完成签到,获得积分10
刚刚
arT发布了新的文献求助10
1秒前
2秒前
李健的应助被张子文采纳,获得10
2秒前
fufukinase发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
3秒前
4秒前
4秒前
可爱的函函的应助被Xiaoyuan采纳,获得10
4秒前
Ray的应助被Evelyn采纳,获得10
5秒前
何为何谓何忆完成签到,获得积分20
5秒前
辛勤小鸭子完成签到,获得积分10
5秒前
5秒前
七彩螺旋完成签到,获得积分10
5秒前
ww发布了新的文献求助10
6秒前
6秒前
tang发布了新的文献求助10
6秒前
黄湘完成签到,获得积分10
7秒前
Ava的应助被12581采纳,获得10
7秒前
7秒前
7秒前
傲娇可仁完成签到,获得积分10
8秒前
七彩螺旋发布了新的文献求助10
8秒前
WY完成签到 ,获得积分10
8秒前
义力古玛发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
机智白枫完成签到,获得积分10
9秒前
业主小丹完成签到,获得积分10
9秒前
10秒前
robert2021给好好说话的求助进行了留言
10秒前
10秒前
www发布了新的文献求助10
11秒前
灵巧幻露发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171099
求助须知:如何正确求助?哪些是违规求助? 9563824
关于积分的说明 21772514
捐赠科研通 7762641
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554704
邀请新用户注册赠送积分活动 2475690